Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Frequently asked questions
What sector does Cybin Inc. (HELP) operate in?
Cybin Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Cybin Inc. (HELP) current stock price?
As of the latest data, Cybin Inc. stock price is CA$14.43, with a previous close of CA$14.32. Cybin Inc. gained CA$0.11 in the last trading session, representing a 0.77% increase.
What is Cybin Inc. (HELP) current market capitalization?
Cybin Inc. market cap is approximately 1.05 billion.
What is Cybin Inc. (HELP) Earnings Per Share (EPS)?
The trailing EPS is -CA$5.76, and the forward EPS is -CA$4.43.
What is Cybin Inc. (HELP) EBITDA?
Cybin Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -69.63 million.
Does Cybin Inc. (HELP) pay dividends?
No. Cybin Inc. does not pay a dividend.
When is Cybin Inc. (HELP) next earnings report?
Cybin Inc. is expected to release its next earnings report on September 30, 2026.
What is Cybin Inc. (HELP) beta (volatility) score?
Cybin Inc. has a beta of 0.632, indicating lower volatility than the overall market.
